Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2010; 31(02): 51-53
DOI: 10.4103/0971-5851.71655
ORIGINAL ARTICLE

Langerhan′s cell histiocytosis: A single institutional experience

Tejinder Singh
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore - 560 030, India
,
C T Satheesh
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore - 560 030, India
,
L Appaji
Department of Pediatrics Oncology, Kidwai Memorial Institute of Oncology, Bangalore - 560 030, India
,
B S Aruna Kumari
Department of Pediatrics Oncology, Kidwai Memorial Institute of Oncology, Bangalore - 560 030, India
,
H S Mamatha
Department of Pediatrics Oncology, Kidwai Memorial Institute of Oncology, Bangalore - 560 030, India
,
G V Giri
Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Bangalore - 560 030, India
,
Clementina Rama Rao
Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore - 560 030, India
› Author Affiliations Source of Support Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Langerhans cell histiocytosis (LCH) is a disease that primarily affects bone but can be associated with a clinical spectrum that ranges from a solitary bone lesion with a favorable natural history to a multisystem, life-threatening disease process. Aim: We analyzed our single institutional experience of managing children with LCH. Settings and Design: A total of 40 children of LCH, managed in tertiary cancer center in South India in the period from 2001 to 2005, were evaluated retrospectively. Materials and Methods: Clinicopathological features, laboratory findings, treatment modalities and long-term outcome were analyzed. Results: Children were aged between 2 months and 12 years, with a mean of 3 years. Majority of the children were below 5 years of age. Group B constituted a bulk of children. Disseminated cases were less (five patients). Liver function dysfunction was seen in four (10%) children. Pulmonary interstitial infiltrates were seen in two (5%) cases. Diabetes insipidus manifested in three patients. There was one death. Conclusion: A better understanding of the etiology and pathogenesis of LCH will result in more directed and efficacious treatment regimens.

Keywords

Bone lesion - chemotherapy - Langerhan′s cell histiocytosis


Publication History

Article published online:
19 November 2021

© 2010. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ladisch S, Jaffe ES. The histiocytosis. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. 5 th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p.768-85.
  • 2 Haupt R, Nanduri V, Calevo MG, Bernstrand C, Braier JL, Broadbent V, et al. Permanent consequences in LCH patients: A pilot study from the histiocyte society-late effects study group. Pediatr Blood Cancer 2004;42:438-44.
  • 3 Prosch H, Grois N, Prayer D, Waldhauser F, Steiner M, Minkov M, et al. Central diabetes insipidus as presenting symptom of langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:594-9.
  • 4 Maghnie M, Cosi G, Genovese E, Manca-Bitti ML, Cohen A, Secca S, et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000;343:998-1007.
  • 5 Alston RD, Tatevossian RG, McNally RJ, Kelsey A, Birch JM, Eden TO. Incidence and survival of childhood LCH in northwest England from 1954 to 1998. Pediatr Blood Cancer 2007;48:555-60.
  • 6 Schmitz L, Favara BE. Nosology and pathology of LCH. Hematol Clin North Am 1998;12:221-46.
  • 7 Gander H, Heitbeg A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhan′s cell histiocytosis. Med Pediatr Oncol 1994;23:72-80.
  • 8 Minkov M, Grois N, Heitger A, Potschger U, Westermeir T, Gadner H. Treatment of multisystem LCH. Results of DAL-HX 83 and DAL-HL 90 studies. DAL-HX study group. Klin Padiatr 2000;212:139-44.
  • 9 Chu T, D′Angio GJ, Favara B, Ladisch S, Nesbit M, Pritchard J. Histiocytosis syndromes in children. Writing Group of the Histiocyte Society. Lancet 1987;2:41-2.
  • 10 Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M, et al. Contempory classification of histiocyte disorders. The WHO Committee on Histocytic/Reticulum cell proliferations. Reclassification Working Group of the Histiocytic Society. Med Pediatr Oncol 1997;29:157-66.
  • 11 Broadbent V, Gadner H, Komp DM, Ladisch S. Histiocytosis syndromes in children; II. Approach to the clinical and laboratory evaluation of children with LCH. Clinical Writing Group of the Histiocyte Society. Med Pediatr Oncol 1989;17:492-5.
  • 12 Schmidt S, Eich G, Hanquinet S, Tschappeler H, Waibel P, Gudinchet F. Extra osseous involvement of LCH in children. Pediatr Radiol 2004;34:313-21.
  • 13 Gander H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, et al. A randomized trial of treatment for multisystem LCH. J Pediatr 2001;138:728-34.